Having trouble accessing articles? Reset your cache.

Immatics reels in $75M from Celgene in first cell therapy deal

Immatics netted its largest upfront cash haul yet in an option deal with Celgene to develop TCR-based cell therapies to treat solid tumors.

The $75 million upfront payment is the largest one-time cash infusion for

Read the full 348 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE